dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | de las Heras, Begoña |
dc.contributor.author | Saini, Kamal S. |
dc.contributor.author | Boyle, Frances |
dc.contributor.author | Ades, Felipe |
dc.contributor.author | de Azambuja, Evandro |
dc.contributor.author | Bozovic-Spasojevic, Ivana |
dc.contributor.author | Capelan Rodríguez, Marta |
dc.date.accessioned | 2021-11-05T11:36:58Z |
dc.date.available | 2021-11-05T11:36:58Z |
dc.date.issued | 2020-12 |
dc.identifier.citation | de las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, et al. Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. Oncol Ther. 2020 Dec;8:171–182. |
dc.identifier.issn | 2366-1089 |
dc.identifier.uri | https://hdl.handle.net/11351/6505 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cancer; Immuno-oncology |
dc.description.abstract | The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Oncology And Therapy;8 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | COVID-19 (Malaltia) |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Therapies, Investigational |
dc.title | Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s40487-020-00124-2 |
dc.subject.decs | neoplasias |
dc.subject.decs | /terapia |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | tratamientos en investigación |
dc.relation.publishversion | https://doi.org/10.1007/s40487-020-00124-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [de Las Heras B] Covance Inc., Princeton, NJ, USA. Madrid Medical Doctors Association, Madrid, Spain. [Saini KS] Covance Inc., Princeton, NJ, USA. East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK. [Boyle F] Mater Hospital, Sydney, Australia. [Ades F] Hospital Alemão Oswaldo Cruz, São Paulo, Brazil. [de Azambuja E] Institut Jules Bordet, Brussels, Belgium. Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. [Bozovic-Spasojevic I] Institute for Oncology and Radiology of Serbia, Belgrade, Serbia. [Capelan M] Vall d'Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 32749634 |
dc.identifier.wos | 000555736300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |